{
    "id": 1384,
    "fullName": "ALK G1128A",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK G1128A lies within the protein kinase domain of the Alk protein (UniProt.org). G1128A confers a gain of function to the Alk protein as demonstrated by increased downstream signaling in vitro and transformation in cultured cells (PMID: 21838707).",
            "references": [
                {
                    "id": 527,
                    "pubMedId": 21838707,
                    "title": "Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21838707"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "G1128A",
    "createDate": "08/12/2014",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102032,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29222584C>G",
        "cDna": "c.3383G>C",
        "protein": "p.G1128A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing ALK G1128A was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).",
            "molecularProfile": {
                "id": 1404,
                "profileName": "ALK G1128A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5182,
                    "pubMedId": 27049722,
                    "title": "Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1404,
            "profileName": "ALK G1128A",
            "profileTreatmentApproaches": [
                {
                    "id": 46,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK G1128A"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102032,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29222584C>G",
            "cDna": "c.3383G>C",
            "protein": "p.G1128A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}